Puja Nistala
Expertise in
7
conditions

Dr. Puja Nistala

Hematology | Oncology
The Curators Of The University Of Missouri
1 Hospital Dr, 
Columbia, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
7
conditions
The Curators Of The University Of Missouri
1 Hospital Dr, 
Columbia, MO 

Overview

Puja Nistala is a Hematologist and an Oncologist practicing medicine in Columbia, Missouri.

Dr. Nistala is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Bone Marrow Aspiration.

Dr. Nistala is board certified in American Board Of Internal Medicine/Medical Oncology and American Board Of Internal Medicine/Hematology. She is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 47 clinical trials. Dr. Nistala is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MO

Board Certifications

American Board Of Internal Medicine/Medical Oncology
American Board Of Internal Medicine/Hematology

Fellowships

University of Missouri School of Medicine, Hematology & Oncology

Hospital Affiliations

University Of Missouri Health Care

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

THE CURATORS OF THE UNIVERSITY OF MISSOURI
1 Hospital Dr, Columbia, MO 65212

Additional Areas of Focus

Dr. Nistala has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Pancreatic Cancer
Bladder Cancer
Colorectal Cancer
Testicular Cancer
Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

47 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil
Study Phase: Phase 3
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Suspended
Publish Date: September 04, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
View 9 Less Clinical Trials

3 Total Publications

Dipeptidylpeptidase 4 promotes survival and stemness of acute myeloid leukemia stem cells.
Dipeptidylpeptidase 4 promotes survival and stemness of acute myeloid leukemia stem cells.
Journal: Cell reports
Published: February 27, 2022
Similar Doctors
Expertise in
84
conditions
Dr. Umasankar Ramadoss
Hematology | Oncology
Expertise in
84
conditions
Dr. Umasankar Ramadoss
Hematology | Oncology
Referral may be required

Boone Hospital Center

1600 E Broadway, 
Columbia, MO 
 (1.0 miles away)
573-815-8000
Languages Spoken:
English
See accepted insurances

Umasankar Ramadoss is a Hematologist and an Oncologist practicing medicine in Columbia, Missouri. Dr. Ramadoss is highly rated in 84 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, Bone Marrow Aspiration, and Liver Embolization.

Expertise in
42
conditions
Dr. Tamara V. Hopkins
Hematology | Oncology
Expertise in
42
conditions
Dr. Tamara V. Hopkins
Hematology | Oncology
Referral may be required
1241 W. Stadium Blvd., 
Jefferson City, MO 
 (26.3 miles away)
573-635-5264
Languages Spoken:
English
See accepted insurances

Tamara Hopkins is a Hematologist and an Oncologist practicing medicine in Jefferson City, Missouri. Dr. Hopkins is highly rated in 42 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Endoscopy, and Bone Graft. Dr. Hopkins is board certified in Missouri Dept Of Health/Narcotics&Dangerous Drugs , Missouri State Board Of Registration, American Board Of Internal Medicine/Medical Oncology , and Drug Enforcement Administration .

Expertise in
24
conditions
Dr. Michael C. Trendle
Hematology | Oncology
Expertise in
24
conditions
Dr. Michael C. Trendle
Hematology | Oncology
Referral may be required

Curators Of The University Of Missouri

1 Hospital Dr, 
Columbia, MO 
 (0.1 miles away)
573-882-8445
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Trendle is a Hematologist and an Oncologist practicing medicine in Columbia, Missouri. Dr. Trendle is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Trendle is currently accepting new patients.

Frequently Asked Questions about Dr. Puja Nistala

How do I make an appointment with Dr. Puja Nistala?

You can book an appointment with Dr. Puja Nistala by calling their office at 573-882-4141. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Puja Nistala a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Puja Nistala is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Puja Nistala specialize in?

While Dr. Puja Nistala is a Hematology, they have specific expertise in Breast Cancer, Inflammatory Breast Cancer, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Puja Nistala participate in research or clinical trials?

Yes. Dr. Puja Nistala has published 3 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Puja Nistala's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Puja Nistala accept my insurance?

Dr. Puja Nistala accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 573-882-4141 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nistala's expertise for a condition
ConditionClose
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile